CClinicalTrials.gg
CompletedNCT05475444Updated Jul 27, 2022

PLGA Nanoparticles Entrapping Ciprofloxacin to Treat E-Fecalis Infections in Endodontics

An interventional study of Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels and Ciprofloxacin paste and solution in Bacterial Infections Oral, sponsored by British University In Egypt. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by British University In Egypt · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2020, registered Feb 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Sex
All
01

Study summary

PLGA nanoparticles coated with Chitosan polymer were prepared and then incorporated in In -situ gel to be injected to root canals of patients suffered from bacterial infection of their endodontics.

Read the detailed description

The Clinical procedures:

  1. First visit Treatment plan was discussed with the patients and their acceptance to participate in the study was obtained through an informed consent.

    Coronal restorations and any carious decay were removed, teeth properly restored then rubber dam was applied for isolation. An access cavity was prepared using an appropriate size bur (Bur #3, Veterinary dental equipment, UK) , and the tooth surface was disinfected before entering the root canals using 2.5% sodium hypochlorite, then its effect was inhibited using 5% sodium thiosulphate. The old gutta percha was removed from the coronal two thirds of the root canal using bur #3 without using any solvent. Sterile saline was used for irrigation. Patency was obtained using manual k files #15 (and #10, tooth length was determined using an electronic apex locator (Electronic apex locator J Morita Root ZX, Morita Corporation, Japan). The remaining gutta percha was removed using gradually increasing sizes of manual k files (K- files, Mani, Japan) . Scrubbing of the walls using manual files was done to soak the irrigant (sterile saline) with parts of the bacterial film on the canal walls. Sterile paper point equivalent to the size of largest file reaching the working length was placed for one minute in the canal and located one millimeter away from the tooth length, this represented the first sample for bacteriological assessment (S1) then paper point was placed in 1ml sterile medium. Complete cleaning and shaping of the canal was done using 15 ml of 2.5% sodium hypchlorite as an irrigant with a side vented needle of gauge 27, placed one millimeter from the working length and manual k type files, the master apical file was determined according to each case, where its size was increased 3 times more than the initial file with obtained white dentine chips as well. After complete cleaning and shaping, the action of sodium hypochlorite was inhibited by using 10 ml of 5% sodium thiosulphate. Sodium thiosulphate was flushed from the canal using 5 ml sterile saline. A sterile paper point equivalent to the size of master apical file was placed for one minute in the canal, one millimeter away from the working length to soak the fluid and this represented the second sample for bacteriological assessment (S2), afterwards, paper point is placed in 1ml sterile medium, then the patients were randomly allocated according to the use of an intracanal medications to the five groups for 7 days. Finally, a cotton pellet and temporary filling (Orafill-G) was applied under complete aseptic conditions

  2. Second visit

    • Assessment of the clinical signs and symptoms was done.
  3. Clinical criteria for healing:
  1. No pain with percussion 2. No pain with palpation 3. Tooth asymptomatic and functional If the patient showed these clinical findings, root canals were obturated. If the patient had all or one of them, cleaning, shaping and medication steps were repeated and the patient re-scheduled for another visit after 7 days. If the patient was asymptomatic and the tooth was functional, then a temporary filling was removed under rubber dam isolation. Twenty ml of sterile saline was used to remove the intracanal medicaments until it got out clear from the canal then sterile paper point was placed in the canal one millimeter away from the working length to take the last sample (S3), paper point was placed in 1ml sterile medium, finally master cone adjustment and obturation were done.

These sterile paper points with three samples (S1, S2, S3) were placed separately in sterile falcon tubes, labeled according to the type of medication and the order of the sample. One ml of sterile tryptic soy broth (TSB) supplemented with 0.5% glucose (TSBG) was added to each tube , then tubes were transferred to the microbiology lab within 2-3 hours from sampling procedure in an ice box 4.Microbiological evaluation All microbiological steps were performed in the vicinity of a trilaminar flow cabinet to avoid air contamination of the samples.

  1. Total percentage of bacterial reduction: A total of 100 μl from each sample containing (4mg) drug in addition to Ca (OH)2 paste and (4mg) CIP past were aspirated using a sterile micropipette from each tube. A sterile inoculum was used to add samples to the brain heart media. The samples were labeled according to the groups of medication and incubated for 24 hours at 37 ºC. After incubation, the total number of bacterial counts was estimated
02

Conditions studied

03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 55 is below the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

British University In Egypt is the lead sponsor of 67 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Root canal filled single rooted teeth with post treatment disease manifested by one or more of the following signs and symptoms:
  • History of recurrent acute and/or chronic periapical abscess
  • Pain on palpation and/or percussion at least after one month of previous procedure
  • Radiographic evidence of bone loss either as a new developing lesion or an increase in the size of a pre-existing one.

Exclusion criteria

Exclusion Criteria:

  • Teeth that were badly broken down indicated for extraction or with difficult isolation
  • Immuno-compromised patients.
  • Patients with history of taking antibiotics orally.
  • Periodontally affected teeth.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Paste and solution of ciprofloxacin as Conventional Treatment

    Paste and solution of ciprofloxacin as conventional dosage forms and drugs used to treat endodontics infections. For ciprofloxacin solution is used once daily while the paste form used weekly.

    Device: Ciprofloxacin paste and solution

  • Experimental
    Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel

    Chitosan coated PLGA nanoparticles entrapping ciprofloxacin and incorporated in smart poloxamer gel dosage forms treat endodontics infections

    Device: Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels

Interventions

  • DeviceChitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels

    antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.

    Also known as: Chitosan Coated PLGA nanoparticles, PLGA nanoparticles as smart gels

  • DeviceCiprofloxacin paste and solution

    Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection

06

What researchers measure

Primary outcomes

  1. Determination of Bacterial count by counting bacterial colonies of the sample

    Bacterial count was expected to be decreased by counting bacterial colonies of the sample after treatment and comparing with control without treatment

    Time frame: One week

Secondary outcomes

  1. Determination of the Biofilm inhibition using crystal violet and microplate reader

    Biofilm is to be inhibited and being small by using of stains crystal violet as marker, in order to more accurately identify cells of interest and distinguish from culture debris.

    Time frame: one week

07

Study locations

1 site
  • Mona Arafa
    Cairo, El Sherouk City , Suez Desert Road , Cairo - P.O. Box 43 11837, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05475444
Lead sponsor
British University In Egypt
Responsible party
Mona Gamal Mohamed Afifi Arafa (Associate Professor, British University In Egypt) — Principal investigator
First posted
Jul 27, 2022
Start date
Mar 1, 2020
Primary completion
Mar 8, 2020
Completion
Mar 15, 2020
Last update
Jul 27, 2022

Study contacts

Mona Arafa, Professor
principal investigator · The British University in Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion